



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

USP28-IN-4

Cat. No.:	HY-149230
CAS No.:	2931509-15-6
Molecular Formula:	C ₂₂ H ₁₈ Cl ₂ N ₂ O ₃ S
Molecular Weight:	461.36
Target:	Deubiquitinase
Pathway:	Cell Cycle/DNA Damage
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 25 mg/mL (54.19 mM; ultrasonic and adjust pH to 6 with HCl)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.1675 mL	10.8375 mL	21.6750 mL
	5 mM	0.4335 mL	2.1675 mL	4.3350 mL
	10 mM	0.2168 mL	1.0838 mL	2.1675 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

USP28-IN-4 is a USP28 inhibitor (IC₅₀=0.04 μM) with high selectivity over USP2, USP7, USP8, USP9x, UCHL3 and UCHL5. USP28-IN-4 shows cytotoxicity against cancer cells, down-regulates the cellular level of c-Myc through ubiquitin-proteasome system. USP28-IN-4 also decreases the ankyrase-1/2 level in vitro. USP28-IN-4 enhance the sensitivity of colorectal cancer cells to Regorafenib (HY-10331)^[1].

IC₅₀ & Target

USP28
0.04 μM (IC₅₀)

In Vitro

USP28-IN-4 (compound 9p) (12.5 μM, 15 μM; 3 d) inhibits colony formation of human colorectal cancer cells HCT116 (15 μM) and Ls174T (12.5 μM)^[1].

USP28-IN-4 (20-80 μM; 24 h) down-regulates the level of c-Myc by enhancing its degradation via ubiquitin-proteasome system (UPS)^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line: Human colorectal cancer cells HCT116 and Ls174T

Concentration:	20 μ M, 30 μ M, 50 μ M, and 60 μ M, for Ls174T; 30 μ M, 50 μ M, 60 μ M and 80 μ M for HCT116
Incubation Time:	24 h
Result:	Dose-dependently down-regulated the cellular level of c-Myc.

REFERENCES

[1]. Zhou D, et al. Structure-based discovery of potent USP28 inhibitors derived from Vismodegib. Eur J Med Chem. 2023 Jun 5;254:115369.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA